Abstract:PURPOSE:The characteristic expression of DNA damage response proteins in familial breast cancers with BRCA1, BRCA2, or non-BRCA1/2 mutations has not been analyzed in Chinese patients. Our study aimed to assess the differential expression of microcephalin 1 (BRIT1), ATM serine/threonine kinase (ATM), checkpoint kinase 2 (CHEK2), BRCA1, RAD51 recombinase (RAD51), and poly (ADP-ribose) polymerase 1 (PARP-1) and establish the profile of Chinese familial breast cancers with different mutation status.METHODS:We constructed five tissue microarrays from 183 familial breast cancer patients (31 with BRCA1 mutations; 14 with BRCA2 mutations, and 138 with non-BRCA1/2 mutations). The DNA response and repair markers used for immunohistochemistry analysis included BRIT1, ATM, CHEK2, BRCA1, RAD51, and PARP-1. The expressions of these proteins were analyzed in BRCA1/2 mutated tumors. The association between pathologic characteristics with BRCA1/2 mutation status was also analyzed.RESULTS:In familial breast cancer patients, BRCA1 mutated tumors were more frequent with high nuclear grade, estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 negative, low Ki-67, and positive CK5/6. BRCA1 mutated tumors had lower CHEK2 and higher cytoplasmic BRIT1 expression than BRCA2 and non-BRCA1/2 mutation tumors. BRCA2-associated tumors showed higher CHEK2 and cytoplasmic RAD51 expression than those in other groups. Nuclear PARP-1 expression in BRCA1/2-associated tumors was significantly higher than in non-BRCA1/2 mutation tumors. Moreover, we found quite a few of negative PARP-1 expression cases in BRCA1/2 mutated groups.CONCLUSION:The clinicopathologic findings of BRCA1-associated Chinese familial breast cancers were similar to the results of other studies. Chinese familial breast cancer patients with BRCA1/2 mutations might have distinctive expression of different DNA damage response proteins. The reduced expression of PARP-1 in Chinese BRCA1/2 mutated breast cancer patients could influence the therapeutic outcome of PARP-1 inhibitors.

Expression of BRCA1 Protein in Primary Epithelial Ovarian Cancer

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

Brg1 Gene Mutation and the Protein Expression in Gastric Carcinoma

Expression of BRCA1 and Its Relationship with C-erbB-2 and Ki67 in Sporadic Breast Cancer

[Expression and Clinical Significance of DNAJB11 in Epithelial Ovarian Cancer].

Expression of Octamer-4 in Serous and Mucinous Ovarian Carcinoma.

ABO Blood Groups and Expression of Blood Group Antigens of Epithelial Ovarian Cancer in Chinese Women.

Clinical Significance and Prognostic Value of Extracellular Signal-Regulated Kinases in Epithelial Ovarian Cancer

BRCA mutations in the manifestation and treatment of ovarian cancer.

BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays

VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma

[Expressions of VEGF/VEGFRs and Activation of STATs in Ovarian Carcinoma].

Expression and Clinical Significance of EGFR and Ki67 in Epithelialovarian Cancer

THE EXPRESSION OF MKP-1 AND p-ERK; IN PRIMARY OVARIAN EPITHELIAL TUMOR TISSUES

The Expression of Aquaporin-1 and Aquaporin-5 in Epithelial Ovarian Tumors and Its Clinic Signifiance.

[The Expression of MKP-1 and P-Erk(1/2) in Primary Ovarian Epithelial Tumor Tissues].

Expression of PDCD5 protein in epithelial ovarian cancer and it's relationship with survival

Relationship Between Expression of Estrogen and Progesterone Receptor and Prognosis in Patients with Serous Cystadenocarcinoma of the Ovary

[Expression and Clinical Significance of BRCA1 in Human Esophageal Squamous Cell Carcinoma].

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Association Of Ethnic-Specific Mutations In Brca1 With An Increased Risk Of Ovarian Cancer

Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.